Kinetics of visual field loss in Usher syndrome type II

Alessandro Iannaccone, Stephen B. Kritchevsky, Maria Laura Ciccarelli, Salvatore A. Tedesco, Claudio Macaluso, William J. Kimberling, Grant Somes

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

PURPOSE. To characterize the kinetics of visual field decay in Usher syndrome type II. METHODS. The area of 137 Goldmann visual fields (GVFs) delimited with the I4e and V4e targets was measured in each eye of 19 patients with an established diagnosis of Usher syndrome type II, and the average interocular GVF area for each patient at each time point was calculated. The average follow-up was 5.58 years. Symptomatic disease duration was defined as years elapsed after symptoms were first noted. The data set (n = 67 for the I4e target; n = 70 for the V4e target) was analyzed with a random coefficient mixed model to identify the best-fit model describing the decay of visual field size over time. The half-life of the residual visual field area (t0.5) was also calculated. RESULTS. The variable that best explained the decay of the GVF area was the duration of symptomatic disease. In an exponential model, the slope estimate for the natural log of the GVF area was -0.172 for the I4e target and -0.136 for the V4e target for each year of symptomatic disease. Accordingly, t0.5 was approximately 4 years for the I4e target and 5 years for the V4e target. These estimates are very similar to those in previous studies of nonsyndromic retinitis pigmentosa (RP). CONCLUSIONS. This study suggests that the kinetics of GVF decline in Usher syndrome type II are, on average, very similar to other forms of RP and that, once the disease becomes symptomatic, GVF deterioration follows stereotyped kinetics, even in patients with late-onset retinal disease.

Original languageEnglish (US)
Pages (from-to)784-792
Number of pages9
JournalInvestigative Ophthalmology and Visual Science
Volume45
Issue number3
DOIs
StatePublished - Mar 1 2004

Fingerprint

Usher Syndromes
Visual Fields
Retinitis Pigmentosa
Retinal Diseases
Half-Life

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Iannaccone, A., Kritchevsky, S. B., Ciccarelli, M. L., Tedesco, S. A., Macaluso, C., Kimberling, W. J., & Somes, G. (2004). Kinetics of visual field loss in Usher syndrome type II. Investigative Ophthalmology and Visual Science, 45(3), 784-792. https://doi.org/10.1167/iovs.03-0906

Kinetics of visual field loss in Usher syndrome type II. / Iannaccone, Alessandro; Kritchevsky, Stephen B.; Ciccarelli, Maria Laura; Tedesco, Salvatore A.; Macaluso, Claudio; Kimberling, William J.; Somes, Grant.

In: Investigative Ophthalmology and Visual Science, Vol. 45, No. 3, 01.03.2004, p. 784-792.

Research output: Contribution to journalArticle

Iannaccone, A, Kritchevsky, SB, Ciccarelli, ML, Tedesco, SA, Macaluso, C, Kimberling, WJ & Somes, G 2004, 'Kinetics of visual field loss in Usher syndrome type II', Investigative Ophthalmology and Visual Science, vol. 45, no. 3, pp. 784-792. https://doi.org/10.1167/iovs.03-0906
Iannaccone A, Kritchevsky SB, Ciccarelli ML, Tedesco SA, Macaluso C, Kimberling WJ et al. Kinetics of visual field loss in Usher syndrome type II. Investigative Ophthalmology and Visual Science. 2004 Mar 1;45(3):784-792. https://doi.org/10.1167/iovs.03-0906
Iannaccone, Alessandro ; Kritchevsky, Stephen B. ; Ciccarelli, Maria Laura ; Tedesco, Salvatore A. ; Macaluso, Claudio ; Kimberling, William J. ; Somes, Grant. / Kinetics of visual field loss in Usher syndrome type II. In: Investigative Ophthalmology and Visual Science. 2004 ; Vol. 45, No. 3. pp. 784-792.
@article{8f743cc6e85a4a2098cd64c2c649aff7,
title = "Kinetics of visual field loss in Usher syndrome type II",
abstract = "PURPOSE. To characterize the kinetics of visual field decay in Usher syndrome type II. METHODS. The area of 137 Goldmann visual fields (GVFs) delimited with the I4e and V4e targets was measured in each eye of 19 patients with an established diagnosis of Usher syndrome type II, and the average interocular GVF area for each patient at each time point was calculated. The average follow-up was 5.58 years. Symptomatic disease duration was defined as years elapsed after symptoms were first noted. The data set (n = 67 for the I4e target; n = 70 for the V4e target) was analyzed with a random coefficient mixed model to identify the best-fit model describing the decay of visual field size over time. The half-life of the residual visual field area (t0.5) was also calculated. RESULTS. The variable that best explained the decay of the GVF area was the duration of symptomatic disease. In an exponential model, the slope estimate for the natural log of the GVF area was -0.172 for the I4e target and -0.136 for the V4e target for each year of symptomatic disease. Accordingly, t0.5 was approximately 4 years for the I4e target and 5 years for the V4e target. These estimates are very similar to those in previous studies of nonsyndromic retinitis pigmentosa (RP). CONCLUSIONS. This study suggests that the kinetics of GVF decline in Usher syndrome type II are, on average, very similar to other forms of RP and that, once the disease becomes symptomatic, GVF deterioration follows stereotyped kinetics, even in patients with late-onset retinal disease.",
author = "Alessandro Iannaccone and Kritchevsky, {Stephen B.} and Ciccarelli, {Maria Laura} and Tedesco, {Salvatore A.} and Claudio Macaluso and Kimberling, {William J.} and Grant Somes",
year = "2004",
month = "3",
day = "1",
doi = "10.1167/iovs.03-0906",
language = "English (US)",
volume = "45",
pages = "784--792",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "3",

}

TY - JOUR

T1 - Kinetics of visual field loss in Usher syndrome type II

AU - Iannaccone, Alessandro

AU - Kritchevsky, Stephen B.

AU - Ciccarelli, Maria Laura

AU - Tedesco, Salvatore A.

AU - Macaluso, Claudio

AU - Kimberling, William J.

AU - Somes, Grant

PY - 2004/3/1

Y1 - 2004/3/1

N2 - PURPOSE. To characterize the kinetics of visual field decay in Usher syndrome type II. METHODS. The area of 137 Goldmann visual fields (GVFs) delimited with the I4e and V4e targets was measured in each eye of 19 patients with an established diagnosis of Usher syndrome type II, and the average interocular GVF area for each patient at each time point was calculated. The average follow-up was 5.58 years. Symptomatic disease duration was defined as years elapsed after symptoms were first noted. The data set (n = 67 for the I4e target; n = 70 for the V4e target) was analyzed with a random coefficient mixed model to identify the best-fit model describing the decay of visual field size over time. The half-life of the residual visual field area (t0.5) was also calculated. RESULTS. The variable that best explained the decay of the GVF area was the duration of symptomatic disease. In an exponential model, the slope estimate for the natural log of the GVF area was -0.172 for the I4e target and -0.136 for the V4e target for each year of symptomatic disease. Accordingly, t0.5 was approximately 4 years for the I4e target and 5 years for the V4e target. These estimates are very similar to those in previous studies of nonsyndromic retinitis pigmentosa (RP). CONCLUSIONS. This study suggests that the kinetics of GVF decline in Usher syndrome type II are, on average, very similar to other forms of RP and that, once the disease becomes symptomatic, GVF deterioration follows stereotyped kinetics, even in patients with late-onset retinal disease.

AB - PURPOSE. To characterize the kinetics of visual field decay in Usher syndrome type II. METHODS. The area of 137 Goldmann visual fields (GVFs) delimited with the I4e and V4e targets was measured in each eye of 19 patients with an established diagnosis of Usher syndrome type II, and the average interocular GVF area for each patient at each time point was calculated. The average follow-up was 5.58 years. Symptomatic disease duration was defined as years elapsed after symptoms were first noted. The data set (n = 67 for the I4e target; n = 70 for the V4e target) was analyzed with a random coefficient mixed model to identify the best-fit model describing the decay of visual field size over time. The half-life of the residual visual field area (t0.5) was also calculated. RESULTS. The variable that best explained the decay of the GVF area was the duration of symptomatic disease. In an exponential model, the slope estimate for the natural log of the GVF area was -0.172 for the I4e target and -0.136 for the V4e target for each year of symptomatic disease. Accordingly, t0.5 was approximately 4 years for the I4e target and 5 years for the V4e target. These estimates are very similar to those in previous studies of nonsyndromic retinitis pigmentosa (RP). CONCLUSIONS. This study suggests that the kinetics of GVF decline in Usher syndrome type II are, on average, very similar to other forms of RP and that, once the disease becomes symptomatic, GVF deterioration follows stereotyped kinetics, even in patients with late-onset retinal disease.

UR - http://www.scopus.com/inward/record.url?scp=1542427273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542427273&partnerID=8YFLogxK

U2 - 10.1167/iovs.03-0906

DO - 10.1167/iovs.03-0906

M3 - Article

C2 - 14985291

AN - SCOPUS:1542427273

VL - 45

SP - 784

EP - 792

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 3

ER -